Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Uzi Sofer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Beta
- 1.19
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 5.73
Financials
Net Income
$-45.81MEBITDA
$-13.78MFree Cash Flow
$0.00EPS (diluted)
$-0.50Shares Outstanding (diluted)
90.95M+34.5%Operating Expenses
$13.78MCash & Debt
$100.64MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-42.63M | $-0.53 |
| 2024 | $0.00 | $-31.75M | $-0.45 |
| 2023 | $0.00 | $-29.16M | $-0.42 |
| 2022 | $0.00 | $-33.76M | $-0.53 |
| 2021 | $0.00 | $-27.27M | $-0.40 |
| 2020 | $0.00 | $-8.88M | $-0.13 |
| 2019 | $0.00 | $-8.46M | $-0.13 |
Valuation
DRTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
103Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Neutral
…hat also includes the ACAPELLA trial in France and a study at the University of Verona - JERUSALEM, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the completion of patient enrollment in its IMPACT study (Intratumoral Pancreatic Alpha Combination Trial) - a multicenter pilot study evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy …
View source ↗
Earnings
Thu, Nov 19(in 3 months)
Consensus estimate $-0.14 per share
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.50 vs $-0.14miss
- Mon, May 18$-0.26 vs $-0.13miss
- Mon, Mar 9$-0.14 vs $-0.13miss
- Thu, Nov 20$-0.14 vs $-0.12miss
- Mon, Aug 11$-0.13 vs $-0.12miss
- Mon, May 19$-0.12 vs $-0.14beat
Estimates and results for DRTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DRTS officers and directors.
- Bought
- —
- Sold
- $1.6m
0 trades
12 trades
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
- Levy Raphisold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.